4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Marker Therapeutics, Inc. (MRKR) operates in the Biotechnology industry and is headquartered in Houston, United States with about 5 employees. Its market capitalization is roughly $21 million. In the fiscal year ended 2025-12-31, MRKR reported $0M in revenue and ($12M) in net income.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
Interactive charts & full statements → Open the MRKR valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $3M | $0M | — |
| Operating Income (EBIT) | ($12M) | ($11M) | ($11M) | ($20M) | — |
| Net Income | ($12M) | ($11M) | ($8M) | ($30M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($3M) | ($2M) | ($2M) | ($4M) | ($4M) | — |
| Net Income | ($3M) | ($2M) | ($2M) | ($4M) | ($4M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $19M | $22M | $17M | $34M | — |
| Total Liabilities | $2M | $4M | $3M | $15M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MRKR viewer.
About TickerBase · Data methodology & sources